Clinical Trial Results: A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating SBT101 gene therapy in adult adrenomyeloneuropathy (AMN) has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenomyeloneuropathy
• X-linked Adrenoleukodystrophy

Drugs mentioned

• SBT101

Snippet

Sponsor: SwanBio Therapeutics, Inc. | Conditions: AMN, AMN Gene Mutation | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-08-26